National longitudinal cohort of autoimmune hemolytic anemia in China
Official title: National Longitudinal Cohort of Hematological Diseases- Autoimmune Hemolytic Anemia
Run by Institute of Hematology & Blood Diseases Hospital, China · NCT07019038 · Data updated 2026-11-12
This project will follow people with warm, cold, or mixed autoimmune hemolytic anemia treated at a major Tianjin hematology center to see what treatments they receive and how well they do over time.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 9999 (estimated) |
| Sponsor | Institute of Hematology & Blood Diseases Hospital, China Academic / other |
| Locations | 1 site (Tianjin, Tianjin Municipality) |
| Status | Recruiting |
| Started | January 1, 2001 |
| Main results expected | December 31, 2070 |
| Study ends | December 31, 2070 |
| Registry record updated | June 17, 2025 |
| Trial ID | NCT07019038 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
People diagnosed with warm, cold, or mixed autoimmune hemolytic anemia with hemoglobin below 100 g/L who have been treated at the Institute of Hematology & Blood Diseases Hospital (Tianjin) since January 1, 2001 are the intended participants.
✕Probably not a fit
Patients who cannot commit to long-term follow-up, have severe comorbidities or substance dependence that limit reliable data collection, or who were not treated at the enrolling center are unlikely to gain benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational cohort combines retrospective data and prospective follow-up of patients with warm, cold, or mixed autoimmune hemolytic anemia seen at the Institute of Hematology & Blood Diseases Hospital in Tianjin. Investigators will collect demographic and clinical characteristics, biochemical and hematologic indicators, treatment patterns, clinical outcomes (hematologic response, relapse, mortality), long-term post-discontinuation outcomes, and healthcare costs. Retrospective inclusion will cover patients treated since January 1, 2001, while prospective follow-up will monitor ongoing outcomes and resource use. Analyses will describe incidence, identify risk factors, and examine real-world effectiveness of therapies and associations with prognosis.
Why it matters
Potential benefit: If successful, the cohort could clarify which treatments and patient factors are linked to better blood responses and long-term outcomes, helping guide clinical care and resource planning in China.
How similar studies have gone: Prior smaller single-center and multi-center cohorts have informed AIHA natural history and treatment patterns, but large-scale prospective national cohorts in China are scarce and this approach is relatively novel there.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subjects diagnosed with AIHA. * Hemoglobin\<100g/L * Subjects treated at the Institute of Hematology and Blood Diseases Hospital from Jan 1, 2001. Exclusion Criteria: * Subject unlikely to be available for long-term follow-up for any reason (e.g., inability to obtain follow-up data or presence of severe comorbidities). * Subject with alcohol or drug dependence may reduce their compliance with the study. * Subjects that the investigator believes have other reasons that make them unsuitable for inclusion in this study.
Where it's running
-
Red Blood Cell Diseases Center and Regenerative Medicine Center
Tianjin, Tianjin Municipality, China Recruiting
Study contacts
- Study coordinator: Lele Zhang, PhD
- Email: zhanglele@ihcams.ac.cn
- Phone: 15811139278
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
OM336 for autoimmune hemolytic anemia and immune thrombocytopenia
This phase 1 trial will test whether subcutaneously given OM336 is safe and tolerable in adults with relapsed or refractory autoimmune hemolytic anemia or immune thrombocytopenia.
-
Universal (allogeneic) CAR T-cell therapy targeting CD19 and BCMA for relapsed/refractory autoimmune hemolytic anemia
This trial will try a single infusion of universal anti‑CD19/BCMA CAR T-cells for people aged 10 and up whose autoimmune hemolytic anemia has not responded to at least three prior treatments.
-
HY001N cell injection for autoimmune hemolytic anemia after failing three or more treatments
This trial tests whether HY001N cell injections are safe and can help adults with autoimmune hemolytic anemia who have not responded to at least three therapies.
-
In vivo CAR-T therapy Arnovie101 for B cell–mediated autoimmune diseases
This open-label, single-arm study tests Arnovie101, an mRNA-LNP-based in vivo CAR-T therapy, in adults with relapsed or refractory SLE or AIHA to see if it is safe and how the body handles it.
-
Orelabrutinib for relapsed or refractory AIHA
This study tests whether taking orelabrutinib by mouth can help adults with relapsed or refractory autoimmune hemolytic anemia (AIHA).
-
GT801 injection for adults with relapsed/refractory CD19-positive B-cell cancers and autoimmune hemolytic anemia
This trial will test whether GT801 injections help adults with CD19-positive B-cell cancers (B-ALL, CLL, B-NHL) or autoimmune hemolytic anemia that have returned or not responded to prior treatments.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.